Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07729618) titled 'AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma' on July 22.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).

Primary Sponsor: Tongji Hospital

Condition: Unresectable Hepatocellular Carcinoma

Intervention: Other: AI-Assisted Clinical Decision Support Strategy

Recruitment Status: Not recruiting

Phase: N/A

Date of First Enrollment: October 1, 2026

Target Sample Size: 1800

Countries of Recruitment: China

To know more, visit https://clinicaltrials.g...